jacksonjohn750 Posted - 1 week ago

$PCRX

DangDownAgain Posted - 1 week ago

$PCRX Up big again. $HRTX Down again. Inflation won’t be kind to HRTX

jacksonjohn750 Posted - 2 weeks ago

$PCRX they should sell this to China and put the shareholders out of misery

DangDownAgain Posted - 2 weeks ago

$HRTX Back down again tomorrow. Buy $PCRX the industry leader

jacksonjohn750 Posted - 2 weeks ago

$PCRX 52 week low this week or next?

DangDownAgain Posted - 2 weeks ago

$PCRX going to $40, $HRTX going back under $1 by end of year.

HorizonBull Posted - 2 weeks ago

$PCRX moving toward 20- by mid summer and 20- by EOY.

DangDownAgain Posted - 2 weeks ago

$HRTX Buy $PCRX and sell HRTX. It’s a no brainer

Stock_Titan Posted - 3 weeks ago

$PCRX Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/PCRX/pacira-bio-sciences-to-participate-in-fireside-chat-at-the-23rd-sz2dzerfgyxz.html

greentip Posted - 1 month ago

$PCRX Why are you PCRX Longs still over here! Your stock price is in a long-term downtrend. The major competitor in your space (Heron Therapeutics, HRTX) is taking more and more of your market share every day with Zynrelef, which going head-to-head with your Exparel. This is reflected in the Heron Therapeutics Stock price as of late. Best of luck to you...

CarpeDiem_ Posted - 1 month ago

$PCRX Hrtx is coming for yall

Stock_Titan Posted - 1 month ago

$PCRX Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee https://www.stocktitan.net/news/PCRX/pacira-bio-sciences-announces-pcrx-201-granted-regenerative-medicine-l7vhkcx7h9ax.html

Rediska Posted - 1 month ago

$PCRX very interesting buying point 31.50. with first exit at 35. Don't forget to set stop losses.

GpHarma Posted - 1 month ago

$PCRX any chance we move up after this Fireside Chat @ the Barclays?

AnaChart Posted - 1 month ago

$PCRX https://anachart.com/wp-content/uploads/ana_temp/1709820135_soc-img.jpg

Stock_Titan Posted - 1 month ago

$PCRX Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference https://www.stocktitan.net/news/PCRX/pacira-bio-sciences-to-participate-in-fireside-chat-at-the-barclays-7u5e600pafob.html

DailyStocksPicks Posted - 1 month ago

$PRGO might be considered oversold following its latest earnings announcement. Despite surpassing earnings expectations, the company reported sales figures that didn't meet projections. This, coupled with a 2024 outlook that didn’t align with analyst expectations, could have contributed to negative market sentiment. However, it's crucial to recognize that Perrigo also reported record net sales for the fourth quarter and the full year of 2023, demonstrating solid operational performance. Moreover, the launch of an efficiency program suggests strategic steps are being taken to enhance future growth. These factors, when juxtaposed with the stock’s market reaction, suggest that Perrigo’s current stock valuation might not fully reflect the company’s underlying financial health and future potential. $CORT, $SUPN, $PCRX, $JAZZ For more details https://youtu.be/VTKGlSe8Cn4

DailyStocksPicks Posted - 1 month ago

$PRGO Perrigo Company plc's stock might be considered oversold following its latest earnings announcement. Despite surpassing earnings expectations, the company reported sales figures that didn't meet projections. This, coupled with a 2024 outlook that didn’t align with analyst expectations, could have contributed to negative market sentiment. However, it's crucial to recognize that Perrigo also reported record net sales for the fourth quarter and the full year of 2023, demonstrating solid operational performance. Moreover, the launch of an efficiency program suggests strategic steps are being taken to enhance future growth. These factors, when juxtaposed with the stock’s market reaction, suggest that Perrigo’s current stock valuation might not fully reflect the company’s underlying financial health and future potential. $CORT $SUPN $PCRX $JAZZ For more details https://youtu.be/5WSzPuYhAF0

briefingcom Posted - 02/29/24

$PCRX: Pacira BioSciences beats by $0.09, reports revs in-line; guides FY24 revs below consensus https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240229080419PCRX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

H73 Posted - 02/29/24

$PCRX good numbers except for the revenue forecast. Is the new CEO shooting a bit low so he can exceed them ?

DonCorleone77 Posted - 02/29/24

$PCRX Pacira reports Q4 EPS 89c, consensus 88c Reports Q4 revenue $181.2M, consensus $181.66M. "Now that I have spent several weeks working with the Pacira team, I am even more enthusiastic to lead this great company as we build upon an impressive foundation of success," said Frank Lee, chief executive officer of Pacira BioSciences. "Looking ahead, we are sharply focused on driving long-term growth, furthering our patient centric culture and establishing high standards for operational excellence. Throughout 2024, we plan to advance the launch of EXPAREL in two key lower extremity nerve blocks and prepare for the significant catalyst ahead in NOPAIN. In parallel, we are taking the necessary steps to reallocate our efforts and resources to ensure the organization is best positioned for sustainable success. We have the people, the purpose, and the products to change the course of pain management and, hopefully, to help save patients from the deadly effects of opioid addiction."

epsguid Posted - 02/29/24

$PCRX reported earnings of $0.71, consensus was $0.71 via @eWhispers #epsmeet http://eps.sh/d/pcrx

Stock_Titan Posted - 02/29/24

$PCRX Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results https://www.stocktitan.net/news/PCRX/pacira-bio-sciences-reports-fourth-quarter-and-full-year-2023-tdknap7v0pul.html

StockInvest_us Posted - 02/29/24

Signal alert: $PCRX - GoldenStar https://stockinvest.us/l/UNV3y9iMmF

Stock_Titan Posted - 2 months ago

$PCRX Pacira to Report 2023 Financial Results on Thursday February 29, 2024 https://www.stocktitan.net/news/PCRX/pacira-to-report-2023-financial-results-on-thursday-february-29-to74fi9jct79.html

Stock_Titan Posted - 2 months ago

$PCRX Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy https://www.stocktitan.net/news/PCRX/pacira-announces-publication-of-pivotal-study-of-exparel-as-a-7bhluo2qtupm.html

StockInvest_us Posted - 2 months ago

Signal alert: $PCRX - GoldenStar https://stockinvest.us/l/XTuVaigznb

briefingcom Posted - 2 months ago

$PCRX: Pacira BioSciences has been awarded a national group purchasing agreement for Brand Pharmaceuticals with Premier https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240207080942PCRX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Stock_Titan Posted - 2 months ago

$PCRX Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. https://www.stocktitan.net/news/PCRX/pacira-bio-sciences-awarded-brand-pharmaceuticals-agreement-with-7dzsd1xv3khn.html

MetroStockTrader Posted - 3 months ago

$HRTX $PCRX For the people who know more than me about Zynrelef and Exparel… Is Pacira’s Exparel the most direct competitor? Are Exparel and Zynrelef similar or is one superior? I believe that Zynrelef can claim “extended release”. Is the same true for Exparel? Does Zynrelef have any other direct, non-opioid competitors? Thank you.